Ann: Kazia's paxalisib SNO data, page-5

You left out the best part !!

The study has not at this stage shown a clear survival benefit for paxalisib in comparison to
historical controls. In terms of PFS, the proportion of patients alive and progression-free at
1 ME Hegi, A-C Desirens, T Gorlia, et al. N Engl J Med (2005); 352:997-1003
six months (PFS6) was 96%, which compares favourably to an historical control of 58%2
.
However, the authors note that PFS can be a complex endpoint to interpret in DIPG trials due
to the confounding effect of incidental radiological changes associated with radiation therapy.